Cellectis is pivoting from allogeneic CAR-T development to become an in vivo gene editing company, discontinuing its lasme-cel and eti-cel programs.
Feature|Articles|April 2, 2026
Trump Administration’s Leadership Carousel Across Key Agencies
Author(s)Nicholas Jacobus
Since the start of President Trump's second term, the FDA, CDC, CDER, and CBER have collectively cycled through more than a dozen leadership changes.
Advertisement
Advertisement
Since the beginning of President Trump’s second term, leadership at some of the nation’s most critical agencies underwent eye-catching amounts of turnover.
Related to this article
Novo Nordisk rebrands as "Novo" under it's "Lasting health starts now" tagline, pairing both with a new cultural framework called "The Novo Way."
Novartis shareholders share deepened trust issues around the company's dealmaking strategy.
Artisan Partners' David Samra is publicly calling for Novartis to overhaul its board and compensation structure following back-to-back trial failures.
Moonwalk Biosciences has closed a $70 million Series B to advance its adipose-targeted RNAi platform toward first-in-human studies.
Novo partners with Anthropic to deploy Claude for targeted drug discovery workflows and AI-driven software development.
Sling Therapeutics closes a $123 million Series C to advance linsitinib, while Circle Pharma raises an oversubscribed $92.5 million Series E to move CID-165, into clinical development for ER-positive breast cancer.
How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.
Advertisement
Advertisement